Ireland’s cancer insurance protections take effect as minister calls for wider European action
Ireland’s statutory protections requiring insurers to disregard eligible cancer histories in certain mortgage-protection applications took effect on 15 October, giving qualifying survivors a legally enforceable rule rather than relying solely on a voluntary industry code. The change was highlighted by Minister of State Robert Troy at a conference in Brussels on 21 October, where he argued that comparable protections should be advanced across Europe.
The Irish law is deliberately limited in scope. It applies to an application for mortgage-protection insurance connected with the applicant’s principal private residence. To qualify, an applicant must have completed active cancer treatment at least five years earlier and have been in complete remission for at least five years. The statutory disregard applies to cover sought up to €650,000. Above that threshold, normal underwriting applies.
That means the measure is not a general prohibition on insurers considering every aspect of an applicant’s health, nor does it automatically guarantee that a policy will be offered on particular terms. It concerns the applicant’s cancer-related medical history, for the specified insurance and home, once the legal conditions are met. The threshold also matters: applications seeking cover above €650,000 remain subject to ordinary underwriting.
From voluntary code to statutory rule
The legislation builds on a voluntary code introduced in 2023. Under that earlier arrangement, cancer diagnoses were disregarded after seven years from the end of treatment, or after five years for people diagnosed before the age of 18. The code applied to mortgage-protection cover up to €500,000. The new law places the right on a statutory footing, sets a five-year period regardless of age at diagnosis and raises the cover threshold to €650,000.
The Act, formally titled the Insurance (Disregard of Certain Medical History and Miscellaneous Provisions) Act 2026, was signed into law in July and commenced on 15 October. The Government says the way the measure operates will be monitored to assess whether protections are being implemented effectively across the market. Commencement establishes the legal framework; it does not, by itself, provide evidence about how consistently individual applications have since been handled.
Mortgage-protection insurance is tied to the practical process of buying or refinancing a home in Ireland. The new rule is therefore directed at a defined financial barrier: an eligible applicant should not have their past cancer diagnosis counted in the specified application once the required treatment and remission periods have elapsed. Its principal-residence condition distinguishes this arrangement from a wider right covering all insurance products, borrowing or property purchases.
A European debate, not a change to Irish eligibility
At the Brussels meeting, Troy described Ireland’s law as a model for discussion and urged progress towards stronger and more consistent protections across Europe. That appeal was advocacy, not a new European-wide rule. The Irish commencement remains the substantive change for applicants in Ireland; the conference did not expand the domestic law’s eligibility conditions.
Participants at the meeting called for binding national protections, a common five-year standard and effective implementation and appeals mechanisms. Their proposals reflect differences between existing national systems, including waiting periods, financial limits and the products covered. The conference’s call for a broader approach should not be confused with a guarantee that every European country currently offers the same rights.
A separate EU consumer-credit directive is due to apply from 20 November 2026. It limits the use of cancer history for insurance linked to consumer credit, but the conference organisers noted that it does not cover mortgages. That distinction helps explain why advocates are seeking national legislation addressing mortgage cover, even as a separate EU framework approaches. It does not alter the Irish rules that began on 15 October.
The Irish framework therefore combines a clear qualifying period with defined product and value limits. Applicants must meet both the treatment and remission tests, and the policy must relate to their principal private residence. Within those conditions, insurers are required to disregard the cancer history. The measure’s practical reach will depend on eligible applicants being able to use that statutory protection in applications, while the Government’s promised monitoring will be important to understanding implementation over time.
